InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Torres Denice, Director. Insider active across 4 companies, notably GLAUKOS Corp. Cumulatively, 18 filings have been logged. History available since 3 June 2021. The latest transaction was disclosed on 2 January 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Torres Denice
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
623 shares0Common StockSEC:0001820278-26-000002:0
461 shares0Common StockSEC:0001415889-25-015167:0
12,050 sharesCommon StockSEC:0001562180-25-003880:0
12,050 shares0Common StockSEC:0001562180-24-005006:0
1,716 shares0Common StockSEC:0001415889-24-015240:0
990 shares@ US$330.00100.0% of flowCommon StockSEC:0001140361-24-013934:0
895 shares0Common StockSEC:0001415889-24-000632:0
990 shares0Common StockSEC:0000950170-23-029393:0
8,400 shares0Common StockSEC:0001562180-23-005222:0
3,230 shares0Common StockSEC:0001415889-23-009295:0
1,572 shares0Common StockSEC:0001415889-23-000469:0
8,200 shares0Common StockSEC:0001562180-22-004993:0
4,364 shares0Common StockSEC:0001104659-22-068666:0
1,455 shares0Common StockSEC:0001104659-22-001664:0
1,476 shares0Common StockSEC:0001628280-21-023643:0
492 shares0Common StockSEC:0001628280-21-023474:0
3,109 shares0Common StockSEC:0001562180-21-004355:0
2,382 shares0Common StockSEC:0001104659-21-077831:0
18 of 18 declarations
About Torres Denice
Torres Denice is Administrateur and appears in 18 filings in total. Across the 18 most recent sampled filings, the sell amount is EUR 300205, the modal transaction nature is Attribution, and the period runs from 2021-06-07 to 2026-01-07, with filings linked to GLAUKOS Corp, 2seventy bio, Inc., Karuna Therapeutics, Inc. and bluebird bio, Inc.
